Veracyte (VCYT) UBS Global Healthcare Conference 2024 summary

Q3 performance and business highlights

• Core products Decipher and Afirma drove strong testing revenue growth and delivered a 24% adjusted EBITDA margin, exceeding expectations.

• Focus remains on five strategic initiatives, with portfolio realignment including the write-down of Envisia to concentrate resources on high-growth areas.

• Core business represents 90-95% of revenue and is performing well, while some smaller segments are under review for further optimization.

Product performance and growth outlook

• Afirma has achieved 60% market penetration and is expected to grow at high single digits in 2025, driven by investments in product features and customer experience.

• Bethesda V LCD provides a small ASP uplift for Afirma, with incremental Medicare coverage for about 10,000 patients.

• Decipher experienced 30% growth year-to-date, with significant tailwinds from NCCN level one guidelines, expanded indications, and strong clinical evidence.

• Decipher’s metastatic indication is set for a gradual ramp in the second half of 2025, with more substantial impact expected in 2026.

Market opportunity and competitive landscape

• Both Afirma and Decipher target 80% market penetration, with current penetration at 60% for endocrinology diagnostics and 35% for Decipher.

• Sales teams are highly effective, leveraging relationships across academic and community settings to drive adoption.

• No significant substitution risk seen from imaging-based competitors; molecular diagnostics are viewed as complementary.